VEGFA and diabetes mellitus: More effective screening for DR, the development of the non-invasive optical coherence tomography (OCT) in the diagnosis of DME, introduction of intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, as well as improvements in the management of diabetes, have been the key factors in the reduction of visual impairment [6, 7].